Presentation Selected for Best of EASL Summary Slides
Altimmune to Host a NASH KOL and Investor Reception on June 22, 2023
GAITHERSBURG, Md., June 15, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University, will present the results of its 24-week clinical trial of pemvidutide in the treatment of non-alcoholic fatty liver disease (NAFLD) in an oral presentation at the EASL International Liver Congress™ 2023 in Vienna, Austria. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol steatohepatitis (NASH).
Details for the oral presentation are as follows:
Title: | Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, Significantly Reduces Liver Fat, Fibro-inflammation, and Body Weight in Patients with Non-alcoholic Fatty Liver Disease: a 24-week Multicenter, Randomized, Double-blind, Placebo-controlled Trial (Presentation ID OS-063) |
Presenter: | Stephen A. Harrison, M.D., Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University |
Date/Time: | Friday, June 23, 2023, at 8:30 am CEST |
Best of EASL Summary Slide Deck
Dr. Harrison’s presentation was selected for the Best of EASL Summary Slides, a compendium highlighting the most noteworthy contributions to the 2023 EASL program. A copy of the presentation will be accessible on the Events section of the Altimmune website.
NASH KOL and Investor Reception
Altimmune will host a reception in Vienna for NASH KOLs and investors on Thursday, June 22 at 6:30 PM CEST. Please click here if you are interested in attending the reception and to receive additional details.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor & Media Contacts:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
[email protected]
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member